121 results
8-K
EX-99.1
PHIO
Phio Pharmaceuticals Corp
2 Apr 24
Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update
7:30am
meeting of AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. New data was presented on INTASYL PH-894 showing
424B3
PHIO
Phio Pharmaceuticals Corp
28 Dec 23
Prospectus supplement
9:13am
types and tissues;
Ability to target both intracellular and extracellular protein targets;
Efficient uptake by target cells, avoiding the need … as well as the tumor. Intracellular and/or commonly considered “undruggable” targets, such as BRD4, represent a challenge for small molecule
8-K
EX-99.1
PHIO
Phio Pharmaceuticals Corp
9 Nov 23
Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
4:40pm
candidate, PH-762.
Presented new data about its PH-894 INTASYL compound, which targets BRD4, at the AACR-NCI-EORTC International Conference on Molecular … Targets and Cancer Therapeutics in Boston.
Presented new data new data showing INTASYL compound targeting CTLA-4 enhances tumor control at the Annual
424B3
60l1dvbrckfwyhan3
20 Jun 23
Prospectus supplement
9:30am
424B5
zw2he6l
1 Jun 23
Prospectus supplement for primary offering
5:00pm
424B3
tezuyuzi7ux 4yl
10 May 23
Prospectus supplement
4:30pm
424B5
t9shd15c
19 Apr 23
Prospectus supplement for primary offering
5:06pm
8-K
EX-99.1
zme3bsu3 8oqz2clko9v
10 Nov 22
Reports on Third Quarter 2022 Financial Results and Provides Business Update
5:05pm
8-K
EX-99.1
1mt 38l3q6nyugqv3n
11 Aug 22
Phio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
5:00pm
8-K
EX-99.1
azbw 6d1gjtxu
12 May 22
Phio Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
5:00pm